Newsfeed

2017-01-19

CorMatrix Cardiovascular Secures Fifty-six (56) Patents in 2016 Expanding Patent Protection for Extracellular Matrix (ECM®) Based Implantable Devices

The ongoing expansion of this patent portfolio continues to support the Company’s development of novel extracellular matrix (ECM®) based devices and compositions. Of the fifty-six patents, 19 were obtained internationally. CorMatrix currently holds 13 trademarks related to its Extracellular Matrix products and the Company has secured some 128 patents affording significant intellectual property protection in the area of regenerative medicine. Two additional patents, US 8,980,296 and US 8,877,224; along with the issuance of European patent No. 2398502, may significantly address issues surrounding the prevention, reduction, and treatment of myocardial damage and arrhythmic sequelae. Read more >>

2016-12-16

CorMatrix Cardiovascular, Inc. Named as One of Six Innovative Pediatric Medical Device Projects Selected for Seed Grant Awards by Atlantic Pediatric Device Consortium (APDC)

This year's competition began with written proposals for seed grant funding in July 2016. Finalists presented their proposals to the review committee, an audience of peers, and the engineering and medical community in attendance. Awards ranging from $10,000 to $50,000 for product development were given. CorMatrix was awarded a $50,000 grant for their innovation and strides in this regenerative tubular Extracellular Matrix (ECM) mitral valve replacement device. Read more >>

2016-06-28

CorMatrix® CanGaroo® ECM® Envelope Receives CE Mark Approval

CorMatrix® Cardiovascular Incorporated, a company specializing in its extracellular matrix (ECM®) technology announced today that it has received CE mark approval for its CorMatrix® CanGaroo® ECM® Envelope. It is intended for use with cardiac implantable electronic devices (CIED’s) including pacemakers and implantable cardioverter defibrillators (ICD’s). The company received U.S. FDA clearance to market the device in August of 2014. CorMatrix® ECM® acts as a scaffold into which a patient’s cells migrate and integrate, stimulating natural wound healing mechanisms. The CanGaroo® differs from other device pockets on the market because it’s made from porcine derived extracellular matrix (ECM); not synthetic materials. When synthetic material is implanted, inflammatory “M1” macrophages are triggered5, 6 which can result in fibrotic scar formation. Alternatively, the CorMatrix CanGaroo is made from ECM—a natural biologic that triggers a healing, regen­erative “M2” response 5, 6 allowing it to remodel into neo-vascularized tissue that is systemically connected. Read more >>

2016-06-21

CorMatrix® Cardiovascular, Inc. Treats First Patients with New Tyke® Product for Neonates and Infants

First Patients Treated with New Tyke® Product for Neonates and Infants--Extracellular Matrix (ECM®) Now an Alternative for Congenital Heart Defect Repairs in Smaller Structures CorMatrix Cardiovascular, Inc., a leading developer of biomaterials and medical devices, today announced the treatment of the first patients using its CorMatrix® Tyke®, a product specifically designed and cleared for cardiac tissue repairs in neonates and infants. The product received FDA 510(k) clearance in February 2016. CorMatrix® Tyke® is intended for use in neonates and infants for repair of pericardial structures, as an epicardial covering for damaged or repaired cardiac structures, as a patch material for intracardiac defects, septal defects and annulus repair, suture-line buttressing, and cardiac repair. Tyke® is made of 2 layers of CorMatrix® ECM® as compared to the 4 layers of the current CorMatrix® ECM® for Cardiac Tissue Repair, therefore providing a thinner product for smaller repairs. Read more >>

2016-03-17

CorMatrix® Cardiovascular, Inc. Treats First Patient in Its US Clinical Study for CorMatrix® ECM® Tricuspid Valve at Franciscan St. Francis Health Indianapolis, IN

CorMatrix announces treatment of the first patient to receive their tissue engineered regenerative CorMatrix® ECM® Tricuspid Valve. The operation was performed by Marc Gerdisch, MD, FACS, FACC, Chief of Cardiovascular and Thoracic Surgery at Franciscan St. Francis Health in Indianapolis. The Company received approval for the CorMatrix® ECM® Tricuspid Heart Valve as an early feasibility study approved through the FDA Investigational Device Exemption (IDE). The implanted, remodeled valve is comprised of the patient’s own tissue and leaves behind no “foreign body” as is the case with all mechanical or prosthetic valve designs. In addition, the CorMatrix® ECM® Tricuspid Heart Valve does not require the long-term anticoagulation therapy associated with the implant of mechanical valves. Read more >>

2016-03-08

CorMatrix Names Andrew M. Green President and Chief Operating Officer

CorMatrix announced effective January 1, 2016 it has appointed Andrew M. Green as President and Chief Operating Officer and Patrick R. Ferguson as National Sales Director. Mr. Green will have responsibility for the Company’s worldwide product lines and operations, reporting to David Camp, CorMatrix’s Chairman and Chief Executive Officer. Mr. Ferguson will have responsibility for US Sales and Marketing, and will report to Mr. Green. Read more >>

2016-03-07

CorMatrix Cardiovascular Inc. Launches New Corporate Website Cormatrix.com

CorMatrix deploys a new corporate website www.cormatrix.com. The site was developed and designed to reinforce and re-educate the market of the benefits extracellular matrix (ECM) offers cardiac and vascular patients. It also seeks to continue supporting and elevating awareness of the CorMatrix brand. Read more >>

2016-02-15

CorMatrix Cardiovascular Inc. Receives 510(k) Clearance for its Tyke™ Implantable Device for Neonate and Infant Cardiac Tissue Repair

Roswell, GA—February 8, 2016 – CorMatrix® Cardiovascular, Inc., (www.cormatrix.com) a leading developer of biomaterial compositions and medical devices for regenerative medicine, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for its CorMatrix® Tyke™, a biomaterial technology derived from the Company’s ECM® technology platform. Read more >>

2015-08-18

Lovell Government Services Award a VA FSS Contract for CorMatrix® ECM® Surgical Implants

Roswell, GA, August 18, 2015– CorMatrix® Cardiovascular Inc. is pleased to announce its first Veterans Health Administration Contract Award through its Federal distribution partner, Lovell Government Services LLC (LGS). The Contract award number #V797D‐50450 enables the VA and other federal organizations to purchase any of the CorMatrix® products at pre‐approved pricing via the Veterans Administration’s FSS Online Schedule. Read more >>

2015-06-16

CorMatrix® Cardiovascular, Inc. Receives Two (2) Additional U.S. Patents for ECM® Biomaterial Compositions

Roswell, GA – June 16, 2015 – CorMatrix® Cardiovascular, Inc., a leading developer of biomaterial compositions and medical devices, today announced the issuance of U.S. Patent No. 9,034,367 entitled Articles for Tissue Regeneration with Biodegradable Polymers. The ‘367 patent covers grafts and compositions comprising a variety of extracellular matrix (ECM®) materials, including small intestine submucosa, stomach submucosa, liver basement membrane and urinary bladder submucosa. ECM® biopolymer grafts and compositions can also include supplemental bioactive agents, such as growth factors, cells, and other pharmacological agents. Read more >>

2016-02-29

CorMatrix® CanGaroo™ Secures International Approval for South America CorMatrix Extends Distribution of Its Implantable Device to Buenos Aires Based, Demedic

Roswell, GA—March 18, 2015. CorMatrix® Cardiovascular, Inc., a leading developer of biomaterials and medical devices, has received international approval from Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) to market the CorMatrix CanGaroo™ ECM® Envelope. The CorMatrix CanGaroo™ ECM® Envelope is intended to securely hold an implantable electronic device to create a stable environment when placed in the body. The devices that may be used with the CorMatrix CanGaroo™ ECM® Envelope include pacemaker pulse generators, defibrillators, or other cardiac implantable electronic devices (CIED). The device was cleared for sale by the United States Food and Drug Administration (FDA) in 2014 and is expected to receive a CE mark later this year for distribution in the European Union (EU). Read more >>

2015-03-04

CorMatrix® Cardiovascular, Inc. Secures Twelve (12) Additional U.S. Patents for ECM® Biomaterial CorMatrix® Bolsters Its Existing Patent Protections with Newly Issued Patents

Roswell, GA—March 4, 2015. CorMatrix® Cardiovascular, Inc., a leading developer of biomaterials and medical devices, today announced the issuance of U.S. Patent Numbers: 8,568,761; 8,753,885; 8,734,841; 8,642,084; 8,771,737; 8,734,842; 8,753,886; 8,735,155; 8,771,737; 8,784,891; 8,785,197 and 8,785,198 directed to CorMatrix’s novel augmented extracellular matrix (ECM®) bioscaffolds. Read more >>

2015-03-02

CorMatrix® Receives U.S. FDA Approval for Tricuspid Heart Valve Study First of Its Kind Investigational Device Exemption (IDE) Early Feasibility Study a Milestone for the Company

Roswell, Georgia – March 02, 2015 – CorMatrix Cardiovascular Inc., a leading developer of biomaterials and medical devices, today announced FDA approval of an Investigational Device Exemption (IDE) for an Early Feasibility Study of its CorMatrix® ECM® Tricuspid Heart Valve. The trial will evaluate the proof of principle and initial clinical safety of the CorMatrix® ECM® Tricuspid Valve at 5 US centers. Up to 15 subjects will undergo tricuspid valve replacement (TVR) with the CorMatrix® ECM® Tricuspid Valve for the surgical management of tricuspid valve disease not amenable to annuloplasty or repair, including tricuspid valve disease secondary to congenital heart disease in pediatric patients (age < 21) and adult endocarditis patients. Read more >>